Methamphetamine Abuse Clinical Trial
Official title:
Combating Craving With Contingency Management: Neuroplasticity and Methamphetamine Abuse in South Africa
Verified date | May 2019 |
Source | University of California, Los Angeles |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will link findings from neuroscience with clinical outcomes using contingency management (CM) to identify changes in brain structure and function that emerge during purely behavioral therapy for methamphetamine (MA) use.
Status | Completed |
Enrollment | 28 |
Est. completion date | February 15, 2018 |
Est. primary completion date | February 15, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - provide voluntary informed consent - meet DSM-5 criteria for MA or amphetamine use disorder - provide at least one urine sample positive for MA/amphetamine metabolites during screening (i.e. prior to the commencement of the study). - aged 18-45 - right-handed - English-speaking Exclusion Criteria: - currently receiving treatment for stimulant addiction or needing more intensive treatment than outpatient care - meet DSM-5 criteria for substance use disorder other than nicotine - unable to attend 4+ visits during the 2-week screening period or to complete measures - Physical or mental illness that would require intervention that would alter imaging or that would interfere with safe study participation - pregnant, claustrophobic, or have metal prostheses, cardiac pacemakers, or metal clips that are incompatible with the scanner - HIV positive status - unable to comprehend written or spoken English - currently taking psychiatric medication |
Country | Name | City | State |
---|---|---|---|
South Africa | Department of Psychiatry at Groote Schuur Hospital | Cape Town |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles | University of Cape Town |
South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Responses to Contingency Management | urine samples documenting methamphetamine abstinence | 8 weeks | |
Primary | fMRI Measures | measures of resting state connectivity | Change b/w baseline and 8 Weeks | |
Secondary | Stop Signal Task | measure of inhibitory control | Change b/w baseline and 8 Weeks | |
Secondary | Continuous Performance Task | test of sustained attention | Change b/w baseline and 8 Weeks | |
Secondary | Stroop | test of inhibitory control | Change b/w baseline and 8 Weeks | |
Secondary | Balloon Analog Risk Task | measure of risk taking and decision making | Change b/w baseline and 8 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Recruiting |
NCT04927143 -
Encouraging Abstinence Behavior in a Drug Epidemic
|
Phase 2 | |
Completed |
NCT03226223 -
Pharmacogenetics of Naltrexone for Stimulant Abuse
|
Phase 2 | |
Not yet recruiting |
NCT05593796 -
Cognitive Behavioral Therapy(CBT) in Treatment of Methamphetamine Use Disorder
|
N/A | |
Recruiting |
NCT04616625 -
Cardiovascular Effects of Prenatal Methamphetamine Exposure
|
||
Completed |
NCT04061941 -
Change in Cognitive Function in Stimulant Users
|
||
Completed |
NCT01967381 -
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
|
Early Phase 1 | |
Terminated |
NCT01019707 -
Safety Assessment of Atomoxetine With MA IV Administration
|
Phase 1 | |
Completed |
NCT01011829 -
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
|
Phase 2 | |
Active, not recruiting |
NCT04706624 -
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
|
N/A | |
Recruiting |
NCT05700994 -
Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)
|
N/A | |
Completed |
NCT04109014 -
FASTLANE II: Reducing Sex, Drug, and Mental Health Risk
|
N/A | |
Completed |
NCT03336866 -
Study of Antibody for Methamphetamine Outpatient Therapy
|
Phase 1/Phase 2 | |
Completed |
NCT01822132 -
Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade
|
N/A | |
Completed |
NCT01062451 -
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
|
Phase 1 | |
Not yet recruiting |
NCT06233799 -
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
|
Phase 3 | |
Recruiting |
NCT05521854 -
Contingency Management for Drug Use: Does Age Matter?
|
N/A | |
Completed |
NCT01063205 -
NAC as a Potential Treatment for Methamphetamine Dependence
|
Phase 1 | |
Not yet recruiting |
NCT05334914 -
ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals
|
N/A | |
Terminated |
NCT05034874 -
Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
|
Phase 2 |